Acriridone derivatives have become a research hotspot in the field of medicine in recent years due to their good antibacterial, anti-inflammatory, anti-malarial, and anti-cancer activities. This type of compound has a rigid planar structure of a macrocyclic conjugated system and can be embedded or Electrostatic attraction binds to DNA. Among them, 9-aminoacridine derivatives have good pharmacological and biological activities, and some of them have been used clinically as DNA embedding reagents. As an important pharmaceutical intermediate, 9-Oxo-10(9H)-acridineacetic acid has also received increasing attention. Cridanimod (9-Oxo-10(9H)-acridineacetic acid) is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression. Cridanimod is a small-molecule immunomodulator and interferon inducer.
9-Oxo-10(9H)-acridineacetic acid , also known as Cridanimod or XBIO-101, is a small molecule that can increase progesterone receptor (PR) expression, with potential antineoplastic adjuvant activity. Cridanimod is able to induce the expression of PR in endometrial cancer. This could increase the sensitivity of endometrial cancer cells to progestin monotherapy. In combination with a progestin, cancer cells could be eradicated through increased PR-mediated signaling, leading to an inhibition of luteinizing hormone (LH) release from the pituitary gland, via a negative feedback mechanism, and, eventually, an inhibition of estrogen release from the ovaries. This leads to an inhibition of cellular growth in estrogen-dependent tumor cells.
9-Oxo-10(9H)-acridineacetic acid is a reagent for pre-column derivatization of amino acids for fluorescent determination in HPLC and it is also a building block in pharmaceutics.
ChEBI: Cridanimod is a member of acridines. It is functionally related to an acridone.